Showing results (1-10 of 408) with videos related to
Sort By:
Pageof 41
Clinical Calcium|February 3, 2009
[Novel phosphate binders under development]Masahide Mizobuchi, Daisuke Sanada, Tadao AkizawaClinical Calcium|January 8, 2008
[Basic and clinical aspects of calcimimetics. The pathogesis and treatment of secondary hyperparathyroidism]Masahide Mizobuchi, Tadao AkizawaContributions to Nephrology|August 26, 2011
Biocompatible characteristics of high-performance membranesSusumu Uda, Masahide Mizobuchi, Tadao AkizawaClinical Calcium|June 30, 2010
[CKD-MBD (chronic kidney disease-mineral and bone disorder). CKD-MBD: chronic kidney disease-mineral and bone disorder]Masahide Mizobuchi, Yumie Aoshima, Tadao AkizawaClinical Calcium|December 3, 2011
[Bone and calcium update; diagnosis and therapy of metabolic bone disease update. Advances in treatment of CKD-MBD]Masahide Mizobuchi, Ai Nakazawa, Tadao AkizawaClinical Calcium|July 4, 2006
[Vitamin D metabolism and chronic kidney disease]Hirokazu Honda, Daisuke Sanada, Tadao AkizawaBone|May 16, 2009
Vitamin D and vascular calcification in chronic kidney diseaseMasahide Mizobuchi, Hiroaki Ogata, Fumihiko Koiwa, et al.NDT Plus|May 19, 2015
Clinical significance of parathyroid intervention on CKD-MBD managementHiroaki Ogata, Masahide Mizobuchi, Fumihiko Koiwa, et al.Clinical and Experimental Nephrology|December 23, 2016
Research on kidney and mineral metabolism in Japan: past, present, and futureMasahide Mizobuchi, Hiroaki Ogata, Fumihiko Koiwa, et al.Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|August 24, 2017
RAS Inhibitor Is Not Associated With Cardiovascular Benefits in Patients Undergoing Hemodialysis in JapanMasahide Mizobuchi, Hiroaki Ogata, Yoshihiro Onishi, et al.Pageof 41